{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa&page=2",
    "query": {
      "condition": "Epidermolysis Bullosa",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:11:36.648Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02654483",
      "title": "Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "VPD-737",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jean Yuh Tang",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2016-08-31",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654483"
    },
    {
      "nct_id": "NCT04227106",
      "title": "Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "EB-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abeona Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-01-10",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04227106"
    },
    {
      "nct_id": "NCT06073132",
      "title": "An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "AC-203",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TWi Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-04-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 7,
      "location_summary": "Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06073132"
    },
    {
      "nct_id": "NCT02670330",
      "title": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101-6.0 cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 152,
      "start_date": "2015-06-09",
      "completion_date": "2018-09-03",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670330"
    },
    {
      "nct_id": "NCT00533572",
      "title": "Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-08",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2015-05-27",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533572"
    },
    {
      "nct_id": "NCT04140786",
      "title": "Optimizing IV Gentamicin in JEB",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Junctional Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Gentamicin Sulfate, Injectable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Days and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-10-31",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140786"
    },
    {
      "nct_id": "NCT05143190",
      "title": "Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "PTR-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix Tissue Repair, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-12-02",
      "completion_date": "2022-08-09",
      "has_results": false,
      "last_update_posted_date": "2022-11-21",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • New York, New York",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05143190"
    },
    {
      "nct_id": "NCT03389308",
      "title": "Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Epidermolysis Bullosa Simplex"
      ],
      "interventions": [
        {
          "name": "diacerein 1% ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Castle Creek Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "6 Months to 99 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-12-01",
      "completion_date": "2020-04-17",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03389308"
    },
    {
      "nct_id": "NCT01768026",
      "title": "Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lotus Tissue Repair, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2013-02",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2013-05-21",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768026"
    },
    {
      "nct_id": "NCT01033552",
      "title": "Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Mesenchymal stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Bone marrow or umbilical cord blood (UCG) stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-01",
      "completion_date": "2021-08-12",
      "has_results": true,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-05-22T09:11:36.648Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01033552"
    }
  ]
}